Premium
Phenotypic vs. Target‐Based Drug Discovery for First‐in‐Class Medicines
Author(s) -
Swinney D C
Publication year - 2013
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.236
Subject(s) - clinical pharmacology , rationalization (economics) , drug discovery , computational biology , identification (biology) , drug class , phenotype , phenotypic screening , drug , biology , pharmacology , bioinformatics , genetics , gene , political science , law , botany
Current drug discovery strategies include both molecular and empirical approaches. The molecular approaches are predominantly hypothesis‐driven and are referred to as target‐based. The empirical approaches are referred to as phenotypic because they rely on phenotypic measures of response. A recent analysis revealed the phenotypic approaches to be the more successful strategy for small‐molecule, first‐in‐class medicines. The rationalization for this success was the unbiased identification of the molecular mechanism of action (MMOA). Clinical Pharmacology & Therapeutics (2013); 93 4, 299–301. doi: 10.1038/clpt.2012.236